Literature DB >> 19871491

BACTERIOSTATIC EFFECT OF HUMAN SERA ON GROUP A STREPTOCOCCI : I. TYPE-SPECIFIC ANTIBODIES IN SERA OF PATIENTS CONVALESCING FROM GROUP A STREPTOCOCCAL PHARYNGITIS.

S Rothbard1.   

Abstract

1. Type-specific antibodies were demonstrated by the indirect bacteriostatic test in sera from human adults convalescing from group A streptococcal infection of the upper respiratory tract. The time of appearance of the antibodies varied from 3 to 5 weeks; and they persisted in 2 patients for at least 37 weeks after the onset of the infection. 2. The specificity of the antibody response in one serum was tested with strains of 7 heterologous types; in another, with 6; and in the third, with 2; but in no instance were cross-reactions observed. Moreover, each convalescent serum showed approximately equal bacteriostasis for 7 different strains of the same type as that which caused the infection. 3. The antibodies were specifically absorbed from the serum by homologous heat-killed streptococci, but not significantly by strains of heterologous types. 4. The specific M antigen of the streptococcal cell with its respective antibody, and not the T substance, appeared to be concerned in the reaction. 5. In spite of numerous technical difficulties inherent in the method, this bacteriostatic test provides a useful procedure for studying type-specific immunity in streptococcal infections.

Entities:  

Year:  1945        PMID: 19871491      PMCID: PMC2135540          DOI: 10.1084/jem.82.2.93

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  INVESTIGATIONS OF MENINGOCOCCAL INFECTION. III. THE BACTERICIDAL ACTION OF NORMAL AND IMMUNE SERA FOR THE MENINGOCOCCUS.

Authors:  L Thomas; J H Dingle
Journal:  J Clin Invest       Date:  1943-05       Impact factor: 14.808

2.  THE IMMUNE RESPONSE OF HUMAN BEINGS TO BRIEF INFECTIONS WITH PNEUMOCOCCUS.

Authors:  M Heidelberger; D G Anderson
Journal:  J Clin Invest       Date:  1944-09       Impact factor: 14.808

3.  GROUP A HEMOLYTIC STREPTOCOCCUS ANTIBODIES. I. GRIFFITH TYPE AGGLUTININ AND ANTISTREPTOLYSIN TITERS IN NORMAL MEN AND IN ACUTE INFECTIONS.

Authors:  L A Rantz; W M Kirby; A H Jacobs
Journal:  J Clin Invest       Date:  1943-05       Impact factor: 14.808

4.  PRECIPITATION AND AGGLUTINATION TESTS WITH THE HEMOLYTIC STREPTOCOCCUS. TITRATION OF "M" AND "T" ANTI-BODIES IN HUMAN SERA.

Authors:  R A Thomas
Journal:  Science       Date:  1944-12-15       Impact factor: 47.728

5.  TYPING GROUP A HEMOLYTIC STREPTOCOCCI BY M PRECIPITIN REACTIONS IN CAPILLARY PIPETTES.

Authors:  H F Swift; A T Wilson; R C Lancefield
Journal:  J Exp Med       Date:  1943-08-01       Impact factor: 14.307

6.  TYPE-SPECIFIC ANTIGENS, M AND T, OF MATT AND GLOSSY VARIANTS OF GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1940-03-31       Impact factor: 14.307

7.  ANTIGENIC PROPERTIES OF THE TYPE-SPECIFIC SUBSTANCE DERIVED FROM GROUP A HEMOLYTIC STREPTOCOCCI.

Authors:  G K Hirst; R C Lancefield
Journal:  J Exp Med       Date:  1939-02-28       Impact factor: 14.307

8.  BACTERIOSTATIC EFFECT OF HUMAN SERA ON GROUP A STREPTOCOCCI : II. COMPARATIVE BACTERIOSTATIC EFFECT OF NORMAL WHOLE BLOOD FROM DIFFERENT ANIMAL SPECIES IN THE PRESENCE OF HUMAN CONVALESCENT SERA.

Authors:  S Rothbard
Journal:  J Exp Med       Date:  1945-08-01       Impact factor: 14.307

9.  OBSERVATIONS ON THE PHAGOCYTOSIS OF THE PNEUMOCOCCUS BY HUMAN WHOLE BLOOD : I. THE NORMAL PHAGOCYTIC TITRE, AND THE ANTI-PHAGOCYTIC EFFECT OF THE SPECIFIC SOLUBLE SUBSTANCE.

Authors:  H K Ward
Journal:  J Exp Med       Date:  1930-04-30       Impact factor: 14.307

10.  STUDIES ON THE HEMOLYTIC STREPTOCOCCUS OF HUMAN ORIGIN : II. OBSERVATIONS ON THE PROTECTIVE MECHANISM AGAINST THE VIRULENT VARIANTS.

Authors:  C Lyons; H K Ward
Journal:  J Exp Med       Date:  1935-03-31       Impact factor: 14.307

View more
  19 in total

Review 1.  Streptococcal M protein: molecular design and biological behavior.

Authors:  V A Fischetti
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

2.  Murine model of recurrent group G streptococcal cellulitis: no evidence of protective immunity.

Authors:  A L Bisno; J M Gaviria
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

3.  Factors involved in the induction of non-specific resistance to streptococcal infection in mice by endotoxin.

Authors:  J G MICHAEL; B F MASSELL
Journal:  J Exp Med       Date:  1962-07-01       Impact factor: 14.307

4.  Factors affecting the chain length of group A streptococci. I. Demonstration of a metabolically active chain-splitting system.

Authors:  R D EKSTEDT; G H STOLLERMAN
Journal:  J Exp Med       Date:  1960-10-01       Impact factor: 14.307

5.  Persistence of type-specific antibodies in man following infection with group A streptococci.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1959-08-01       Impact factor: 14.307

6.  The ability of group A streptococci killed by heat or mercury arc irradiation to resist ingestion by phagocytes.

Authors:  G G WILEY; A T WILSON
Journal:  J Exp Med       Date:  1956-01-01       Impact factor: 14.307

7.  Preparation and antigenicity of M protein released from group A, type 1 streptococcal cell walls by phage-associated lysin.

Authors:  F S KANTOR; R M COLE
Journal:  J Exp Med       Date:  1960-07-01       Impact factor: 14.307

8.  The occurrence of two M antigens in certain group A streptococci related to type 14.

Authors:  G G WILEY; A T WILSON
Journal:  J Exp Med       Date:  1961-02-01       Impact factor: 14.307

9.  Localization of streptococcal antigens in tissues. I. Histologic distribution and persistence of M protein, types 1, 5, 12, and 19 in the tissues of the mouse.

Authors:  M H KAPLAN
Journal:  J Exp Med       Date:  1958-03-01       Impact factor: 14.307

10.  Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1957-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.